Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 8

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Authors Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P

Published Date June 2012 Volume 2012:8 Pages 295—306

DOI http://dx.doi.org/10.2147/TCRM.S24239

Received 20 April 2012, Accepted 14 May 2012, Published 19 June 2012

Athanasios D Anastasilakis,1 Konstantinos A Toulis,1 Stergios A Polyzos,2 Chrysostomos D Anastasilakis,3 Polyzois Makras4

1Department of Endocrinology, 424 General Military Hospital, 2Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 3Department of Pharmacology, 424 General Military Hospital, Thessaloniki; 4Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece

Abstract: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turnover markers, a continuous marked increase in bone mineral density at all sites, and a marked decrease in the risk of vertebral, hip, and nonvertebral fractures in women with postmenopausal osteoporosis. Therefore, it could be considered as an effective alternative to previous bisphosphonate treatment as well as first-line treatment of severe osteoporosis. Cost-effectiveness studies support this suggestion. In addition, denosumab seems to be the safest treatment option in patients with impaired renal function. Denosumab is characterized by reversibility of its effect after treatment discontinuation, in contrast with bisphosphonates. Large-scale clinical trials, including the extension of FREEDOM trial for up to 5 years, are reassuring for its safety. However, given its brief post-market period, vigilance regarding adverse events related to putative RANKL inhibition in tissues other than bone, as well as those related to bone turnover oversuppression, is advised.

Keywords: adverse event, denosumab, efficacy, fracture, osteoporosis, safety

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The occurrence of cerebrovascular atherosclerosis in Alzheimer’s disease patients

Yuan J, Wen G, Li Y, Liu C

Clinical Interventions in Aging 2013, 8:581-584

Published Date: 24 May 2013

Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma

Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ, Lee RJ

International Journal of Nanomedicine 2012, 7:5465-5474

Published Date: 16 October 2012

Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers

Wahajuddin, Arora S

International Journal of Nanomedicine 2012, 7:3445-3471

Published Date: 6 July 2012

Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells

Wang Y, Zi XY, Su J, Zhang HX, Zhang XR, Zhu HY, Li JX, Yin M, Yang F, Hu YP.

International Journal of Nanomedicine 2012, 7:2641-2652

Published Date: 28 May 2012

Degradable gene delivery systems based on Pluronics-modified low-molecular-weight polyethylenimine: preparation, characterization, intracellular trafficking, and cellular distribution

Fan W, Wu X, Ding B, Gao J, Cai Z, Zhang W, Yin D, Wang X, Zhu Q, Liu J, Ding X, Gao S

International Journal of Nanomedicine 2012, 7:1127-1138

Published Date: 24 February 2012

Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment

Ma Y, Zheng Y, Zeng X, Jiang L, Cheng H, Liu R, Huang L, Mei L

International Journal of Nanomedicine 2011, 6:2679-2688

Published Date: 1 November 2011

Optimized antimicrobial and antiproliferative activities of titanate nanofibers containing silver

Su YH, Yin ZF, Xin HL, Zhang HQ, Sheng JY, Yang YL, Du J, Ling CQ

International Journal of Nanomedicine 2011, 6:1579-1586

Published Date: 2 August 2011

Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer

Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, Ha SH, Kang DH

International Journal of Nanomedicine 2011, 6:1415-1427

Published Date: 6 July 2011

Reversible exposure of hydrophobic residues on albumin as a novel strategy for formulation of nanodelivery vehicles for taxanes

Garro AG, Beltramo DM, Alasino RV, Leonhard V, Heredia V, Bianco ID

International Journal of Nanomedicine 2011, 6:1193-1200

Published Date: 13 June 2011